<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38391" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Angioedema</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Memon</surname>
            <given-names>Ruba J.</given-names>
          </name>
          <aff>Saint Joseph Mercy Oakland</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tiwari</surname>
            <given-names>Vivekanand</given-names>
          </name>
          <aff>Dartmouth Hitchcock Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ruba Memon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vivekanand Tiwari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38391.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Angioedema is non-pitting edema that involves subcutaneous and/or submucosal layers of tissue that affects the face, lips, neck, and extremities, oral cavity, larynx, and/or gut. It becomes life-threatening when it involves the larynx. This activity examines the differential diagnosis of this condition and how to properly evaluate a patient presenting with it. This activity highlights the role of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the classification of angioedema.</p></list-item><list-item><p>Describe the presentation of angioedema.</p></list-item><list-item><p>Summarize the treatment and management options available for angioedema.</p></list-item><list-item><p>Identify the role of the interprofessional team for improving care coordination and communication to advance the treatment of angioedema.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38391">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38391.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Angioedema is defined as " subcutaneous tissues and/or submucosal tissues circumscribed non-pitting edema affecting lips, face, neck, and extremities oral cavity, larynx, and gut." It becomes life-threatening when it involves the larynx, while intestinal angioedema is painful and mimics acute abdomen.<xref ref-type="bibr" rid="article-38391.r1">[1]</xref><xref ref-type="bibr" rid="article-38391.r2">[2]</xref></p>
        <p>Angioedema was first described in 1882 by Quincke, then by Osler in 1888 (hereditary angioedema), and finally in 1963 by Donaldson et al (the role of C1 inhibitor).<xref ref-type="bibr" rid="article-38391.r3">[3]</xref></p>
        <p>
<bold>Classification of angioedema</bold>
</p>
        <p>Acquired</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergic (histaminergic angioedema) associated with anaphylaxis</p>
          </list-item>
          <list-item>
            <p>Non-allergic (non-histaminergic angioedema), presenting isolated or in combination with urticaria</p>
          </list-item>
          <list-item>
            <p>Drug-induced, e.g., angiotensin-converting enzyme inhibitors and non-steroidal anti-inflammatory drugs</p>
          </list-item>
          <list-item>
            <p>Complement-mediated secondary to acquired deficiency of C1-inhibitor</p>
          </list-item>
          <list-item>
            <p>Idiopathic which is subdivided into histaminergic and non-histaminergic</p>
          </list-item>
        </list>
        <p>Hereditary forms</p>
        <list list-type="bullet">
          <list-item>
            <p>C1-Inhibitor deficiency divided into type 1 (lack of C1-inhibitor molecule) and typed 2 (dysfunctional C1-inhibitor molecule) with normal C1 inhibitor.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38391.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p><bold>Inherited</bold> (hereditary angioedema): Mutations in the gene encoding for C1-inhibitor cause hereditary angioedema and it is an autosomal dominant condition.</p>
        <p><bold>Acquired:</bold>&#x000a0;lymphoproliferative disorders, autoimmune, neoplastic, infection and drug-induced.<xref ref-type="bibr" rid="article-38391.r1">[1]</xref></p>
      </sec>
      <sec id="article-38391.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>A retrospective study showed angioedema was the second most common disorder after asthma for hospitalization in New York State. African Americans made up 42% of these angioedema admissions.<xref ref-type="bibr" rid="article-38391.r4">[4]</xref>&#x000a0;Hereditary angioedema is a rare autosomal dominant condition and affects 1/50,000 individuals.<xref ref-type="bibr" rid="article-38391.r5">[5]</xref><xref ref-type="bibr" rid="article-38391.r6">[6]</xref>&#x000a0;A Swedish study showed hereditary angioedema affected females more severely compared to males.<xref ref-type="bibr" rid="article-38391.r7">[7]</xref></p>
      </sec>
      <sec id="article-38391.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In describing pathophysiology, angioedema is classified as histamine-mediated angioedema and bradykinin-mediated angioedema</p>
        <p><bold>Histamine-mediated angioedema</bold> is the most common and is secondary to mast-cells and basophil activation.</p>
        <p><bold>Bradykinin-mediated angioedema</bold> (hereditary angioedema, acquired C1-inhibitor deficiency and angiotensin-converting&#x000a0;enzyme inhibitor-associated angioedema). Allergic reactions and hives do not trigger this condition. C1-inhibitor is a regulator of complement and the contact system; if deficient or dysfunctional it causes activation of the contact system resulting in uncontrolled production of kallikrein leading to proteolysis of high-molecular-weight kininogen and bradykinin, leading to edema by increasing in vascular permeability. Bradykinin-mediated angioedema is seen in:</p>
        <list list-type="bullet">
          <list-item>
            <p>C1 inhibitor deficiency: Excessive production of bradykinin</p>
          </list-item>
          <list-item>
            <p>Angiotensin-converting enzyme inhibitor-associated angioedema: Decreased degradation of bradykinin<xref ref-type="bibr" rid="article-38391.r8">[8]</xref><xref ref-type="bibr" rid="article-38391.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Histamine and bradykinin increase localized microvascular permeability.<xref ref-type="bibr" rid="article-38391.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>NSAID induced: cyclooxygenase 1 inhibitor affects arachnoid acid metabolism, leukotriene/prostaglandin binding to the receptor or may be IgE mediated<xref ref-type="bibr" rid="article-38391.r1">[1]</xref><xref ref-type="bibr" rid="article-38391.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Genetics:</bold>
</p>
        <p>Hereditary angioedema can be secondary to&#x000a0;F12&#x000a0;gene,&#x000a0;angiopoietin-1, and plasminogen or some unknown gene mutation.<xref ref-type="bibr" rid="article-38391.r2">[2]</xref><xref ref-type="bibr" rid="article-38391.r10">[10]</xref></p>
        <p>C1 inhibitor is a serine protease inhibitor (SERPIN) <xref ref-type="bibr" rid="article-38391.r2">[2]</xref>&#x000a0;C1 inhibitor deficiency is associated with&#x000a0; SERPING 1 mutation or mutated genes which encode for metabolizing and functioning enzymes of bradykinin.<xref ref-type="bibr" rid="article-38391.r11">[11]</xref>&#x000a0;Abnormal accumulation of C1 inhibitor in dominant harmful disease affects plasma levels of hereditary angioedema type 1.<xref ref-type="bibr" rid="article-38391.r12">[12]</xref></p>
      </sec>
      <sec id="article-38391.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The presentation can be acute or chronic.</p>
        <p>
<bold>Histaminergic angioedema</bold>
</p>
        <p>Symptoms can involve different systems including skin (Urticaria, flushing, pruritus), Respiratory (bronchospasm), GI symptoms (abdominal pain and vomiting).<xref ref-type="bibr" rid="article-38391.r1">[1]</xref>&#x000a0; Onset is within 60 minutes of allergen exposure and may last for one to two days.<xref ref-type="bibr" rid="article-38391.r1">[1]</xref></p>
        <p>Etiologies: Drugs, foods, latex, and insect stings.<xref ref-type="bibr" rid="article-38391.r13">[13]</xref></p>
        <p>While comparing the bradykinin-mediated angioedema with histaminergic angioedema, the former has the following characteristics:</p>
        <list list-type="bullet">
          <list-item>
            <p>It is not associated with urticaria</p>
          </list-item>
          <list-item>
            <p>More severe and longer duration</p>
          </list-item>
          <list-item>
            <p>Has associated abdominal symptoms&#x000a0;<xref ref-type="bibr" rid="article-38391.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Acquired angioedema related to angiotensin-converting enzyme (ACE) inhibitor</bold>
</p>
        <p>It clinically presents as&#x000a0;angioedema without urticaria or itching<xref ref-type="bibr" rid="article-38391.r14">[14]</xref>&#x000a0;It is&#x000a0;common in African-Americans.<xref ref-type="bibr" rid="article-38391.r15">[15]</xref>&#x000a0;It&#x000a0;can develop anytime but common in the first week of exposure.<xref ref-type="bibr" rid="article-38391.r9">[9]</xref></p>
        <p>
<bold>Nonsteroidal anti-inflammatory disease-induced angioedema</bold>
</p>
        <p>NSAID induced drug reactions include angioedema presenting with urticaria and facial swelling.<xref ref-type="bibr" rid="article-38391.r16">[16]</xref></p>
        <p><bold>Hereditary angioedema</bold>&#x000a0;begins in childhood or young adulthood, gets worse at puberty and presents as recurrent episodes of swelling or abdominal pain.<xref ref-type="bibr" rid="article-38391.r17">[17]</xref><xref ref-type="bibr" rid="article-38391.r18">[18]</xref><xref ref-type="bibr" rid="article-38391.r19">[19]</xref><xref ref-type="bibr" rid="article-38391.r20">[20]</xref>&#x000a0;Patients can develop prominent prodromal symptoms like erythema marginatum (erythematous, serpentine,non-pruritic rash).<xref ref-type="bibr" rid="article-38391.r21">[21]</xref>&#x000a0;An acute attack takes one day to peak and resolves in two to three days.<xref ref-type="bibr" rid="article-38391.r22">[22]</xref></p>
        <p>
<bold>Acquired angioedema with C1 inhibitor deficiency&#x000a0;</bold>
</p>
        <p>Acquired C1 inhibitor deficiency presents similarly to hereditary angioedema. However, the low C1 inhibitor in many cases is from an underlying lymphoproliferative disorder which increases protein consumption and an antibody against C1-INH causing overproduction of bradykinin.<xref ref-type="bibr" rid="article-38391.r13">[13]</xref></p>
        <p>
<bold>Physical examination</bold>
</p>
        <p>Vital signs, level of consciousness, as well as a thorough ski, head, neck, respiratory and abdomen evaluation should be completed.<xref ref-type="bibr" rid="article-38391.r1">[1]</xref></p>
        <p>General monitoring of angioedema in the Emergency room include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Oxygen saturation</p>
          </list-item>
          <list-item>
            <p>Cardiac status</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38391.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>The initial evaluation in the Emergency room</bold>
</p>
        <p>A specific drug and family history is needed along with screening blood work for C4 for hereditary angioedema and tryptase for angioedema with anaphylaxis. These labs when drawn during acute attacks are useful during follow-ups. In the case of anaphylaxis, (tryptase is normal in hereditary angioedema one and two but will be elevated in cases of anaphylaxis and other mast cell disorders associated with angioedema)<xref ref-type="bibr" rid="article-38391.r13">[13]</xref>. Flexible fiberoptic laryngoscopy may be done to evaluate the involvement of tongue and larynx in patients with head, neck and upper airway symptoms.<xref ref-type="bibr" rid="article-38391.r13">[13]</xref></p>
        <p>Clear differentiation between histamine-induced vs. bradykinin-induced&#x000a0;angioedema can be life-saving.<xref ref-type="bibr" rid="article-38391.r23">[23]</xref></p>
        <p><bold>Hereditary angioedema type 1:</bold> C1 inhibitor function low, C1-Inhibitor level low, and C4 level low</p>
        <p><bold>Hereditary angioedema type 2</bold>: C1 inhibitor function and C4 level will be low, but the C1 inhibitor level will be normal or high.<xref ref-type="bibr" rid="article-38391.r24">[24]</xref></p>
        <p>Confirm them by repeating the blood test.&#x000a0;</p>
        <p><bold>Acquired C1-inhibitor deficiency</bold>: Low C1-inhibitor antigen and function and low C1q.<xref ref-type="bibr" rid="article-38391.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-38391.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Antihistamine, corticosteroids, and epinephrine are treatments of <bold>histaminergic angioedema</bold>.<xref ref-type="bibr" rid="article-38391.r1">[1]</xref><xref ref-type="bibr" rid="article-38391.r25">[25]</xref></p>
        <p>Treatment of <bold>Bradykinin-mediated angioedema</bold> is often resistant to standard therapies such as epinephrine,&#x000a0;glucocorticoids or antihistamines.<xref ref-type="bibr" rid="article-38391.r13">[13]</xref></p>
        <p>
<bold>Hereditary angioedema&#x000a0;</bold>
<bold>(On-demand treatment)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treat airway via intubation or surgical airway intervention. Treatment should be as early as possible.&#x000a0;Hereditary angioedema attacks should be treated with C1 Inhibitor concentrate,&#x000a0;<xref ref-type="bibr" rid="article-38391.r26">[26]</xref> ecallantide (Kallikrein inhibitor) or icatibant (bradykinin-receptor antagonist).<xref ref-type="bibr" rid="article-38391.r27">[27]</xref>&#x000a0;Icatibant is an effective home-based, on-demand treatment.<xref ref-type="bibr" rid="article-38391.r28">[28]</xref></p>
          </list-item>
        </list>
        <p><bold>Pre-procedural </bold>(<bold>short-term) prophylaxis</bold></p>
        <p>Short-term prophylaxis before high-risk procedures in high-risk individuals.&#x000a0;<xref ref-type="bibr" rid="article-38391.r2">[2]</xref>&#x000a0;Anesthesiologists must be aware of guideline-based treatment for hereditary and acquired angioedema.&#x000a0;<xref ref-type="bibr" rid="article-38391.r29">[29]</xref></p>
        <p>
<bold>Long-term prophylaxis</bold>
</p>
        <p>C1 Inhibitor is the first-line long-term prophylaxis, while the androgens are used as second-line agents.<xref ref-type="bibr" rid="article-38391.r2">[2]</xref>&#x000a0;</p>
        <p><bold>Hereditary angioedema with mutations in the F12 gene is</bold> treated as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Discontinuing trigger factors (estrogen-containing oral contraceptives, hormonal replacement therapy, angiotensin-converting enzyme inhibitors)</p>
          </list-item>
          <list-item>
            <p>Treating with plasma-derived C1 inhibitor for acute attacks. &#x000a0;Preventing attacks with progestins, tranexamic acid, and danazol.<xref ref-type="bibr" rid="article-38391.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Acquired&#x000a0;angioedema related to angiotensin-converting enzyme (ACE) inhibitor</bold>
</p>
        <p>Treatment is with antihistamines, epinephrine, and glucocorticoids.<xref ref-type="bibr" rid="article-38391.r9">[9]</xref>&#x000a0;Care should be taken to stop the offending ACE inhibitor, and the&#x000a0;patient should be not rechallenged with any of the ACE inhibitors in the future.</p>
        <p><bold>Acquired C1 inhibitor deficiency angioedema</bold>&#x000a0;</p>
        <p>Majority cases are asymptomatic and respond to immunochemotherapy<xref ref-type="bibr" rid="article-38391.r31">[31]</xref>&#x000a0;Treatment of acute attacks with icatibant and plasma-derived&#x000a0;C1 inhibitor concentrate, and prophylaxis is with rituximab with or without chemotherapy and splenectomy.<xref ref-type="bibr" rid="article-38391.r32">[32]</xref></p>
        <p>
<bold>Special considerations:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In pregnancy, the recommended therapy is plasma-derived nano-filtered C1-inhibitor,<xref ref-type="bibr" rid="article-38391.r33">[33]</xref> however, in acute episodes, bradykinin receptor antagonist Icatibant can be used as it is safe with no maternal and fetal adverse effects.<xref ref-type="bibr" rid="article-38391.r34">[34]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In the&#x000a0;pediatric&#x000a0;population, the doses&#x000a0;include&#x000a0;500 units (10-25 kg weighed patients), 1000 units and 1500 Units in patients weighing more than 25kg.<xref ref-type="bibr" rid="article-38391.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>Plasma-derived&#x000a0;C1 esterase inhibitor is safe and efficacious in pediatric patients below 12 years.<xref ref-type="bibr" rid="article-38391.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Icatibant is a well-tolerated medication in the&#x000a0;pediatric group&#x000a0;and might have&#x000a0;a role in treating angiotensin II receptor blocker induced angioedema.<xref ref-type="bibr" rid="article-38391.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Recombinant human C1 esterase inhibitor for acute hereditary angioedema treatment has a persistent response for three days.<xref ref-type="bibr" rid="article-38391.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>C1 inhibitor is used in the acute management of hereditary angioedema associated pancreatitis.<xref ref-type="bibr" rid="article-38391.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with life-threatening orolingual angioedema who are treated with recombinant tissue plasminogen activator infusion, have a rapid response after using icatibant treatment.<xref ref-type="bibr" rid="article-38391.r40">[40]</xref></p>
          </list-item>
          <list-item>
            <p>Concurrent use of angiotensin-converting enzyme inhibitors with, dipeptidyl peptidase-4 inhibitors should be monitored closely as dipeptidyl peptidase-4 is also a major enzyme in the degradation pathway of bradykinin like an angiotensin-converting enzyme.<xref ref-type="bibr" rid="article-38391.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>Use of liquid steroids in patients with severe urticaria associated angioedema in a setting of severe dysphagia secondary to anaphylaxis.<xref ref-type="bibr" rid="article-38391.r42">[42]</xref></p>
          </list-item>
          <list-item>
            <p>Use of omalizumab (Anti-immunoglobulin-E antibody) in Idiopathic non-histaminergic acquired angioedema, which is a rare disease resistant to antihistamines.<xref ref-type="bibr" rid="article-38391.r43">[43]</xref><xref ref-type="bibr" rid="article-38391.r44">[44]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38391.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute contact dermatitis</p>
          </list-item>
          <list-item>
            <p>Drug rash with eosinophilia and systemic symptoms</p>
          </list-item>
          <list-item>
            <p>Dermatomyositis</p>
          </list-item>
          <list-item>
            <p>Morbus Morbihan</p>
          </list-item>
          <list-item>
            <p>Superior vena cava syndrome</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Subcutaneous emphysema</p>
          </list-item>
          <list-item>
            <p>Orofacial granulomatosis</p>
          </list-item>
          <list-item>
            <p>Hypocomplementemic urticarial vasculitis syndrome</p>
          </list-item>
          <list-item>
            <p>Clarkson's disease</p>
          </list-item>
          <list-item>
            <p>Gleich's syndrome</p>
          </list-item>
          <list-item>
            <p>A cluster headache</p>
          </list-item>
          <list-item>
            <p>Idiopathic edema&#x000a0;<xref ref-type="bibr" rid="article-38391.r45">[45]</xref></p>
          </list-item>
        </list>
        <p>Angioedema is one of the differential diagnoses in sudden onset of diffuse isolated edema.<xref ref-type="bibr" rid="article-38391.r46">[46]</xref></p>
        <p>C1 inhibitor hereditary angioedema can be misdiagnosed as familial Mediterranean fever.<xref ref-type="bibr" rid="article-38391.r47">[47]</xref></p>
      </sec>
      <sec id="article-38391.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Histaminergic angioedema clinical course is 1 hour of allergen exposure, and it may last for one to two days.<xref ref-type="bibr" rid="article-38391.r1">[1]</xref></p>
        <p>Hereditary angioedema is a rare disease that often leads to delay in diagnosis as well as a misdiagnosis. Other factors leading to a misdiagnosis are unknown&#x000a0;family history, gastrointestinal manifestations of disease without cutaneous involvement.<xref ref-type="bibr" rid="article-38391.r14">[14]</xref></p>
        <p>C1 inhibitor deficiency type 1 and 2 angioedema attacks are worse compared to acquired C1 inhibitor deficiency angioedema.<xref ref-type="bibr" rid="article-38391.r48">[48]</xref></p>
      </sec>
      <sec id="article-38391.s11" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Critical airway occlusion resulting in death</p>
          </list-item>
          <list-item>
            <p>Acute laryngeal, pharynx and tongue swelling<xref ref-type="bibr" rid="article-38391.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Death from asphyxiation<xref ref-type="bibr" rid="article-38391.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Hereditary angioedema associated pancreatitis<xref ref-type="bibr" rid="article-38391.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Physicians should be mindful of cardiovascular instability including bradycardia after recombinant tissue plasminogen inhibitor in patients who take angiotensin-converting enzyme inhibitors<xref ref-type="bibr" rid="article-38391.r50">[50]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38391.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education for Hereditary angioedema:</p>
        <p>Proper training will comfort a patient's intimidating feeling of self-administration of Subcutaneous injections.</p>
        <p>
<bold>For patients</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Individual training for each patient</p>
          </list-item>
          <list-item>
            <p>Teach them the strategy of planning and scheduling</p>
          </list-item>
        </list>
        <p>
<bold>Train parents/caregivers with the following skills</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>C1-inhibitor subcutaneous injection site</p>
          </list-item>
          <list-item>
            <p>Aseptic technique</p>
          </list-item>
          <list-item>
            <p>Needle or syringe preparation</p>
          </list-item>
          <list-item>
            <p>Injection of C1 inhibitor through the subcutaneous route.</p>
          </list-item>
        </list>
        <p>
<bold>Follow-up care</bold>
</p>
        <p>It is important to follow-up closely during the first few months of treatment. Encourage patients to keep a logbook for treatment compliance which should include document and report a breakthrough attack of hereditary angioedema.</p>
      </sec>
      <sec id="article-38391.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p><bold>Hereditary angioedema: the latest studies indicate that i</bold>nterference RNA mediated knockdown of F12 mRNA ( ALN-F12) is an approach for the prophylactic treatment of hereditary angioedema.<xref ref-type="bibr" rid="article-38391.r51">[51]</xref>&#x000a0;Gene therapy in hereditary angioedema may provide an option of durable treatment, but requires further studies for safety and tolerability.<xref ref-type="bibr" rid="article-38391.r52">[52]</xref>&#x000a0;Functional polymorphism KLKB1-428G/A with or without functional F12-46C/T polymorphisms may be helpful as prognostic markers of disease.<xref ref-type="bibr" rid="article-38391.r53">[53]</xref>&#x000a0;One may monitor 6-keto-prostaglandin F1 alpha as it may&#x000a0;be a risk assessment blood marker in&#x000a0;ACE inhibitor-induced angioedema.<xref ref-type="bibr" rid="article-38391.r54">[54]</xref>&#x000a0;Angioedema is best managed by an interprofessional team as it has very high morbidity and mortality. Patients should be referred to the appropriate specialist as soon as possible. Patients admitted with respiratory distress need ICU monitoring, and the anesthesia staff should be notified. A bedside tracheostomy set is highly recommended.</p>
      </sec>
      <sec id="article-38391.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38391&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38391">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/angioedema/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=38391">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38391/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38391">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-38391.s15">
        <fig id="article-38391.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Angioedema <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="angioedema" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-38391.s16">
        <fig id="article-38391.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Angioedema Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="angioe" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-38391.s17">
        <title>References</title>
        <ref id="article-38391.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Depetri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cugno</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Angioedema and emergency medicine: From pathophysiology to diagnosis and treatment.</article-title>
            <source>Eur J Intern Med</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>59</volume>
            <fpage>8</fpage>
            <page-range>8-13</page-range>
            <pub-id pub-id-type="pmid">30220453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Magerl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ansotegui</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ayg&#x000f6;ren-P&#x000fc;rs&#x000fc;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Betschel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bork</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Balle Boysen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Farkas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grumach</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hide</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Katelaris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lockey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Longhurst</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lumry</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Martinez-Saguer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Moldovan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pawankar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rosenwasser</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Borges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zuraw</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update.</article-title>
            <source>Allergy</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>8</issue>
            <fpage>1575</fpage>
            <page-range>1575-1596</page-range>
            <pub-id pub-id-type="pmid">29318628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reshef</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kidon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leibovich</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The Story of Angioedema: from Quincke to Bradykinin.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-39</page-range>
            <pub-id pub-id-type="pmid">27287037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Teitel</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Pattern of hospitalizations for angioedema in New York between 1990 and 2003.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-66</page-range>
            <pub-id pub-id-type="pmid">16136766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrejevi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koro&#x00161;ec</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>&#x00160;ilar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ko&#x00161;nik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mijanovi&#x00107;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bona&#x0010d;i-Nikoli&#x00107;</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rijavec</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hereditary Angioedema Due to C1 Inhibitor Deficiency in Serbia: Two Novel Mutations and Evidence of Genotype-Phenotype Association.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>e0142174</fpage>
            <pub-id pub-id-type="pmid">26535898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasr</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Manson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Al Wahshi</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Longhurst</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Optimizing hereditary angioedema management through tailored treatment approaches.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2016</year>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-31</page-range>
            <pub-id pub-id-type="pmid">26496459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nordenfelt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rkander</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mallbris</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lindfors</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wahlgren</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Hereditary Angioedema in Swedish Adults: Report From the National Cohort.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2016</year>
            <month>May</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>540</fpage>
            <page-range>540-5</page-range>
            <pub-id pub-id-type="pmid">26540175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>483</fpage>
            <page-range>483-495</page-range>
            <pub-id pub-id-type="pmid">28687104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Monteleone</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>1377</fpage>
            <page-range>1377-1382</page-range>
            <pub-id pub-id-type="pmid">28994183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bork</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wulff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Witzke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hardt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations.</article-title>
            <source>Allergy</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>70</volume>
            <issue>8</issue>
            <fpage>1004</fpage>
            <page-range>1004-12</page-range>
            <pub-id pub-id-type="pmid">25952149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Germenis</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Speletas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Genetics of Hereditary Angioedema Revisited.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <page-range>170-82</page-range>
            <pub-id pub-id-type="pmid">27116602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haslund</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ry&#x000f8;</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Seidelin Majidi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Skipper</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Fryland</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bohn</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Palarasah</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Corydon</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bygum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nejsum</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Dominant-negative SERPING1 variants cause intracellular retention of C1 inhibitor in hereditary angioedema.</article-title>
            <source>J Clin Invest</source>
            <year>2019</year>
            <month>Jan</month>
            <day>02</day>
            <volume>129</volume>
            <issue>1</issue>
            <fpage>388</fpage>
            <page-range>388-405</page-range>
            <pub-id pub-id-type="pmid">30398465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moellman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lindsell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Busse</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Camargo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Lumry</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pines</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Raja</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zuraw</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hiestand</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sinert</surname>
                <given-names>R</given-names>
              </name>
              <collab>American College of Allergy, Asthma &#x00026; Immunology (ACAAI)</collab>
              <collab>Society for Academic Emergency Medicine (SAEM)</collab>
            </person-group>
            <article-title>A consensus parameter for the evaluation and management of angioedema in the emergency department.</article-title>
            <source>Acad Emerg Med</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>469</fpage>
            <page-range>469-84</page-range>
            <pub-id pub-id-type="pmid">24730413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Feo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Parente</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Pasquale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gravante</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nettis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Triggiani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2018</year>
            <volume>175</volume>
            <issue>3</issue>
            <fpage>126</fpage>
            <page-range>126-135</page-range>
            <pub-id pub-id-type="pmid">29393169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Adverse drug effects and angioedema hospitalizations in the United States from 2000 to 2009.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-71</page-range>
            <pub-id pub-id-type="pmid">23406938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berges-Gimeno</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-L&#x000e1;zaro</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Allergic reactions to nonsteroidal anti-inflammatory drugs: is newer better?</article-title>
            <source>Curr Allergy Asthma Rep</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-40</page-range>
            <pub-id pub-id-type="pmid">17504659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuraw</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Hereditary angioedema.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Sep</month>
            <day>04</day>
            <volume>359</volume>
            <issue>10</issue>
            <fpage>1027</fpage>
            <page-range>1027-36</page-range>
            <pub-id pub-id-type="pmid">18768946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000e1;bos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dobru</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mih&#x000e1;ly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dumitrache</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Popa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>N&#x00103;d&#x00103;&#x00219;an</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Moldovan</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Recurrent ascites: a need to evaluate for hereditary angio-oedema.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Nov</month>
            <day>04</day>
            <volume>390</volume>
            <issue>10107</issue>
            <fpage>2119</fpage>
            <page-range>2119-2120</page-range>
            <pub-id pub-id-type="pmid">29115243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keeney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Halalau</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anchoring bias in a case of recurrent abdominal pain.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>Oct</month>
            <day>04</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">28978589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nanda</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Elenburg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Assa'ad</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of pediatric hereditary angioedema.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2015</year>
            <season>May-Jun</season>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>392</fpage>
            <page-range>392-5</page-range>
            <pub-id pub-id-type="pmid">25609346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prematta</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Mende</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rhoads</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2009</year>
            <season>Sep-Oct</season>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>506</fpage>
            <page-range>506-11</page-range>
            <pub-id pub-id-type="pmid">19843405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yigit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sogut</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lisar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yigit</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Usefulness of C1 esterase inhibitor protein concentrate in the management of hereditary angioedema of oropharyngeal tissue.</article-title>
            <source>Niger J Clin Pract</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>531</fpage>
            <page-range>531-533</page-range>
            <pub-id pub-id-type="pmid">29607870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hahn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Greve</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Bradykinin-induced angioedema: Definition, pathogenesis, clinical presentation, diagnosis and therapy].</article-title>
            <source>HNO</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>12</issue>
            <fpage>885</fpage>
            <page-range>885-93; quiz 894-5</page-range>
            <pub-id pub-id-type="pmid">26597136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magerl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Germenis</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>571</fpage>
            <page-range>571-584</page-range>
            <pub-id pub-id-type="pmid">28687110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Busse</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Histaminergic Angioedema.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>467</fpage>
            <page-range>467-481</page-range>
            <pub-id pub-id-type="pmid">28687103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Moldovan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Reshef</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Porebski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stobiecki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Relan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2015</year>
            <season>May-Jun</season>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>417</fpage>
            <page-range>417-23</page-range>
            <pub-id pub-id-type="pmid">25680925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katelaris</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Acute Management of Hereditary Angioedema Attacks.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>541</fpage>
            <page-range>541-556</page-range>
            <pub-id pub-id-type="pmid">28687108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otani</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Lumry</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Hurwitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Holtzman</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Iandoli</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zuraw</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>442</fpage>
            <page-range>442-447.e1</page-range>
            <pub-id pub-id-type="pmid">27818136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacBeth</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Volcheck</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Sprung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weingarten</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>Perioperative course in patients with hereditary or acquired angioedema.</article-title>
            <source>J Clin Anesth</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>34</volume>
            <fpage>385</fpage>
            <page-range>385-91</page-range>
            <pub-id pub-id-type="pmid">27687418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bork</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wulff</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Witzke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hardt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII).</article-title>
            <source>Allergy</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>320</fpage>
            <page-range>320-324</page-range>
            <pub-id pub-id-type="pmid">27905115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bekos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perkmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krauth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raderer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lechner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jaeger</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>9</issue>
            <fpage>2033</fpage>
            <page-range>2033-6</page-range>
            <pub-id pub-id-type="pmid">26795750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gobert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Paule</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ponard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fr&#x000e9;meaux-Bacchi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bouillet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boccon-Gibod</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Drouet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gayet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Launay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mekinian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fain</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>A nationwide study of acquired C1-inhibitor deficiency in France: Characteristics and treatment responses in 92 patients.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>95</volume>
            <issue>33</issue>
            <fpage>e4363</fpage>
            <pub-id pub-id-type="pmid">27537564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vegh</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Martinez-Saguer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wuillemin</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Edelman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams-Herman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rojavin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>216</fpage>
            <page-range>216-221</page-range>
            <pub-id pub-id-type="pmid">28441992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farkas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>K&#x00151;halmi</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Veszeli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>T&#x000f3;th</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>First report of icatibant treatment in a pregnant patient with hereditary angioedema.</article-title>
            <source>J Obstet Gynaecol Res</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>8</issue>
            <fpage>1026</fpage>
            <page-range>1026-8</page-range>
            <pub-id pub-id-type="pmid">27093898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lumry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Soteres</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gower</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schranz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema.</article-title>
            <source>Pediatr Allergy Immunol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>674</fpage>
            <page-range>674-80</page-range>
            <pub-id pub-id-type="pmid">26171584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Craig</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>MacGinnitie</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Plasma-derived C1-INH for managing hereditary angioedema in pediatric patients: A systematic review.</article-title>
            <source>Pediatr Allergy Immunol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>537</fpage>
            <page-range>537-44</page-range>
            <pub-id pub-id-type="pmid">26111105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strassen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Knopf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greve</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of angiotensin receptor blocker-induced angioedema: A case series.</article-title>
            <source>Laryngoscope</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>125</volume>
            <issue>7</issue>
            <fpage>1619</fpage>
            <page-range>1619-23</page-range>
            <pub-id pub-id-type="pmid">25646708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Relan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>452</fpage>
            <page-range>452-455</page-range>
            <pub-id pub-id-type="pmid">28284978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loudin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Modiano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sallay</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rapid Improvement of Pancreatitis Secondary to Hereditary Angioedema with C1 Inhibitor Administration.</article-title>
            <source>Am J Med</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>129</volume>
            <issue>7</issue>
            <fpage>e75</fpage>
            <page-range>e75-6</page-range>
            <pub-id pub-id-type="pmid">27056293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheong</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kleinig</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Icatibant as a Potential Treatment of Life-Threatening Alteplase-Induced Angioedema.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>e36</fpage>
            <page-range>e36-e37</page-range>
            <pub-id pub-id-type="pmid">29097062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Aagaard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Buchwald</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?</article-title>
            <source>Curr Diabetes Rev</source>
            <year>2018</year>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-333</page-range>
            <pub-id pub-id-type="pmid">28201967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peveling-Oberhag</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reimann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weyer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goloborodko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Staubach</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>High-Concentration Liquid Prednisolone Formula: Filling a Therapeutic Niche in Severe Acute Attacks of Urticaria and Angioedema.</article-title>
            <source>Skin Pharmacol Physiol</source>
            <year>2016</year>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-12</page-range>
            <pub-id pub-id-type="pmid">26465879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faisant</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Du Thanh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mansard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Deroux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boccon-Gibod</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bouillet</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.</article-title>
            <source>J Clin Immunol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-84</page-range>
            <pub-id pub-id-type="pmid">27826875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staubach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chapman-Rothe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sieder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Br&#x000e4;utigam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Canvin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.</article-title>
            <source>Allergy</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>71</volume>
            <issue>8</issue>
            <fpage>1135</fpage>
            <page-range>1135-44</page-range>
            <pub-id pub-id-type="pmid">27010957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Longhurst</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Bygum</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>How Not to Be Misled by Disorders Mimicking Angioedema: A Review of Pseudoangioedema.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2016</year>
            <volume>169</volume>
            <issue>3</issue>
            <fpage>163</fpage>
            <page-range>163-70</page-range>
            <pub-id pub-id-type="pmid">27100932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laccourreye</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Delort</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bonfils</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic approach to sudden onset of diffuse isolated oedema of the lips.</article-title>
            <source>Eur Ann Otorhinolaryngol Head Neck Dis</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>134</volume>
            <issue>5</issue>
            <fpage>357</fpage>
            <page-range>357-359</page-range>
            <pub-id pub-id-type="pmid">28082136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akoglu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kesim</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yildiz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Metin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of long term treatments of type I hereditary angioedema in a Turkish family.</article-title>
            <source>An Bras Dermatol</source>
            <year>2017</year>
            <season>Sep-Oct</season>
            <volume>92</volume>
            <issue>5</issue>
            <fpage>655</fpage>
            <page-range>655-660</page-range>
            <pub-id pub-id-type="pmid">29166502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longhurst</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Zanichelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caballero</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bouillet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aberer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fain</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fabien</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Andresen</surname>
                <given-names>I</given-names>
              </name>
              <collab>IOS Study Group</collab>
            </person-group>
            <article-title>Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>188</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <page-range>148-153</page-range>
            <pub-id pub-id-type="pmid">27936514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilbert</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Byard</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Lethal manifestations of angioedema.</article-title>
            <source>Forensic Sci Med Pathol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>494</fpage>
            <page-range>494-497</page-range>
            <pub-id pub-id-type="pmid">30390279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kageyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okanoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suenaga</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular Instability Preceded by Orolingual Angioedema after Alteplase Treatment.</article-title>
            <source>Intern Med</source>
            <year>2016</year>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>409</fpage>
            <page-range>409-12</page-range>
            <pub-id pub-id-type="pmid">26875969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borodovsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Racie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Castoreno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlegel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Akinc</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.</article-title>
            <source>RNA</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-263</page-range>
            <pub-id pub-id-type="pmid">30463937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Emerging Therapies in Hereditary Angioedema.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>585</fpage>
            <page-range>585-595</page-range>
            <pub-id pub-id-type="pmid">28687111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gianni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loules</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zamanakou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kompoti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Csuka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Psarros</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Magerl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moldovan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Speletas</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Farkas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Germenis</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset.</article-title>
            <source>Int Arch Allergy Immunol</source>
            <year>2017</year>
            <volume>174</volume>
            <issue>3-4</issue>
            <fpage>200</fpage>
            <page-range>200-204</page-range>
            <pub-id pub-id-type="pmid">29130992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38391.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Storck</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Strassen</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Potential Biomarkers for the Diagnosis of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.</article-title>
            <source>ORL J Otorhinolaryngol Relat Spec</source>
            <year>2017</year>
            <volume>79</volume>
            <issue>1-2</issue>
            <fpage>85</fpage>
            <page-range>85-92</page-range>
            <pub-id pub-id-type="pmid">28231587</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
